An interventional study of trans-cutaneous auricular sensory stimulation in Ischemic Stroke, Thrombotic Stroke and Autonomic Dysfunction, sponsored by Queen Mary University of London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Queen Mary University of London · Not applicable, Interventional, and Treatment
Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.
Loss of autonomic variability is strongly associated with adverse outcomes after ischaemic stroke. Removing blood clots from the brain by mechanical thrombectomy has revolutionised the management of stroke, but more than 50% of patients do not regain functional independence.(PMID:26898852) Blood pressure (BP) control is important, since low and high BP (BP variability) are strongly associated with poor patient outcomes after thrombectomy. (PMIDs:32961389;31964286) Autonomic dysfunction causes labile blood pressure. Intact autonomic function is required to control blood pressure and potentially improve recovery after stroke. Impairment of baroreflex autonomic function, due to reduced vagal activity is associated with extreme BP variability, leading to further brain injury and cardiovascular complications.(PMID:30371208) Reduced baroreflex control is related to poor patient outcomes after stroke, independent of absolute blood pressure.(PMID:19834010) Reversing baroreflex and vagal dysfunction is, therefore, widely held to have the potential to improve cardiovascular control and patient outcome in this context.(PMID:19834010)
Non-invasive peripheral neuromodulation restores autonomic control. Vagal nerve stimulation improves autonomic control and reverses baroreflex dysfunction (PMIDs:28949064) but this has previously required surgically implanted devices which are expensive and impractical in the context of acute stroke. Afferent Electronic have achieved the same effect as these implantable devices by non-invasive transcutaneous autonomic neuromodulation (TAN). We have used this simple, safe, hand-held, low-cost device to increase vagal activity and baroreflex sensitivity through non-invasive, painless stimulation of nerves located in the outer ear to control blood pressure.
Baroreflex sensitivity can be increased at the bedside by TAN for 30 minutes following acute trauma. If this can be replicated in thrombectomy patients, it will aid recovery and rehabilitation through five complementary mechanisms where it has been clinically demonstrated that increasing vagal nerve activity:
21 studies on the registry are indexed under Thrombotic Stroke; 8 are open to participants now.
This study's enrollment of 36 is below the median of 85 across 13 interventional studies indexed under Thrombotic Stroke.
Browse Thrombotic Stroke studies →Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Compared within Thrombotic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ischemic Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.
Device: trans-cutaneous auricular sensory stimulation
Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off \[blinded to operator\].
Device: trans-cutaneous auricular sensory stimulation
Transcutaneous auricular sensory stimulation
Blood Pressure Variability
Coefficient of variation of systolic blood pressure
Time frame: 0-24h after mechanical thrombectomy
Systolic Blood Pressure Variability.
Systolic blood pressure standard deviation.
Time frame: 0-24h after mechanical thrombectomy
Diastolic Blood Pressure Variability
coefficient of variation- diastolic blood pressure
Time frame: 24h after admission for mechanical thrombectomy
Patients referred for urgent mechanical thrombectomy.
| Milestone | Stimulation - n=18 | Electrode Attachment Only - n=18 |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
Coefficient of variation of systolic blood pressure
| coefficient of variation | Stimulation | Electrode Attachment Only. |
|---|---|---|
| Blood Pressure Variability | 0.106 ± 0.029 | 0.107 ± 0.027 |
Systolic blood pressure standard deviation.
| mmHg | Stimulation - n=18 | Electrode Attachment Only - n=18 |
|---|---|---|
| Systolic Blood Pressure Variability. | 14 ± 5 | 14 ± 4 |
coefficient of variation- diastolic blood pressure
| coefficient of variation | Stimulation | Electrode Attachment Only. |
|---|---|---|
| Diastolic Blood Pressure Variability | 0.136 ± 0.05 | 0.127 ± 0.04 |
Collected over From randomisation until 7 days after thrombectomy. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stimulation - n=18 | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Electrode Attachment Only - n=18 | 2/18 (11.1%) | 0/18 (0%) | 0/18 (0%) |
| Event | Stimulation - n=18 | Electrode Attachment Only - n=18 |
|---|---|---|
| Skin irritationSkin and subcutaneous tissue disorders | 1/18 | 0/18 |
| Anaesthetic complicationRespiratory, thoracic and mediastinal disorders | 1/18 | 0/18 |
| Age, Categorical(Participants) | Stimulation - n=18 | Electrode Attachment Only - n=18 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 5 | 12 |
| >=65 years | 11 | 13 | 24 |
| Age, Continuous(years) | Stimulation - n=18 | Electrode Attachment Only - n=18 | Total |
|---|---|---|---|
| Mean | 69 ± 13 | 69 ± 15 | 69 ± 14 |
| Sex: Female, Male(Participants) | Stimulation - n=18 | Electrode Attachment Only - n=18 | Total |
|---|---|---|---|
| Female | 13 | 9 | 22 |
| Male | 5 | 9 | 14 |
| Race/Ethnicity, Customized(Participants) | Stimulation - n=18 | Electrode Attachment Only - n=18 | Total |
|---|---|---|---|
| Non-white | 8 | 3 | 11 |
| Other | 10 | 15 | 25 |
| Region of Enrollment(participants) | Stimulation - n=18 | Electrode Attachment Only - n=18 | Total |
|---|---|---|---|
| United Kingdom | 18 | 18 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Researchers who provide a methodologically sound proposal approved by an independent review committee intermediary using deidentified data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: No end date.
Access criteria: To achieve aims in approved proposal.
Ran from Apr 2023 to primary completion in Jul 2023, 2 months.
Results were first posted in Jul 2025, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →